Evidence map›Paper›PMID 38374927›Full record

ArticleRespiratory medicine case reports2024

Efficacy of durvalumab plus chemotherapy in small-cell lung cancer with Lambert-Eaton myasthenic syndrome.

Naoya Ishibashi, Toshiharu Tabata, Ryo Nonomura, Yutaka Oshima, Takanobu Sasaki, Hideki Mitomo, Takafumi Sugawara, Motoyasu Sagawa

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Naoya IshibashiDepartment of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Japan.
Toshiharu TabataDepartment of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Japan.
Ryo NonomuraDepartment of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Japan.
Yutaka OshimaDepartment of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Japan.
Takanobu SasakiDepartment of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Japan.
Hideki MitomoDepartment of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Japan.
Takafumi SugawaraDepartment of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Japan.
Motoyasu SagawaDepartment of Thoracic Surgery, Tohoku Medical and Pharmaceutical University Hospital, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lambert-Eaton myasthenic syndrome (LEMS) is a rare disease but is often associated with small-cell lung cancer (SCLC). We discuss the case of a 65-year-old man diagnosed with SCLC-LEMS and treated with carboplatin, etoposide, and durvalumab. Lower extremity weakness and high anti-P/Q voltage-gated calcium channel (VGCC) antibody levels were diagnostic and helpful. The patient showed a reduction in neurological symptoms with treatment for SCLC, including an immune checkpoint inhibitor (ICI), without standard treatment for LEMS. This treatment may be a treatment option, although the recurrence of LEMS as an immune-related adverse events (irAEs) should be noted.

Indexed as

DurvalumabLambert-Eaton myasthenic syndrome (LEMS)Small-cell lung cancer (SCLC)

Identifiers

PMID38374927
PMCPMC10874974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.